JHEP Reports· 2026Q1
Beyond the class effect: Rethinking anticoagulation in liver disease
- 0citations
- Q1SCImago
- 2026year
Short summary
Current hepatology guidelines treat direct oral anticoagulants (DOACs) as a homogeneous class for liver disease, despite their increasing use and potential for molecule-specific differences.
AI-generated from the title and abstract; the full text is not read.
Key points
- DOACs are now widely used for various vascular liver diseases and cirrhosis, not just portal vein thrombosis.
- Existing hepatology guidelines incorrectly assume DOACs are clinically interchangeable.
- The paper advocates for recognizing potential differences between individual DOAC molecules.
AI-generated from the title and abstract; the full text is not read.
Abstract
The use of direct oral anticoagulants (DOACs) has transformed hepatology. Initially introduced as an alternative to vitamin K antagonists and low-molecular-weight heparin for portal vein thrombosis (PVT), DOACs are now increasingly used across the spectrum of vascular liver diseases (VLD) and cirrhosis. Yet, current hepatology guidelines continue to treat DOACs as a homogeneous therapeutic class, assuming that differences between individual molecules have limited clinical relevance (Fig. 1).
The authors' abstract, as published at the source. JHEP Reports, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hepatology
HepatologyMedicine